SpAMDA, also known as spiro-AMDA or as spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine, is a serotonin 5-HT2A receptor antagonist of the phenethylamine family. It is a tricyclic and spiro cyclized phenethylamine and is an analogue of AMDA. The drug shows high affinity for the serotonin 5-HT2A receptor (Ki = 4 nM) and has 5-fold higher affinity than AMDA. Its A2 value for serotonin 5-HT2A receptor antagonism is 79 nM. In addition to the serotonin 5-HT2A receptor, SpAMDA shows 6-fold lower affinity for the serotonin 5-HT2C receptor (Ki = 24 nM), but no affinity for several other targets, such as the dopamine D2 receptor among others. The chemical synthesis of SpAMDA has been described. Various analogues of SpAMDA have been described. SpAMDA was first described in the scientific literature by Richard Glennon and Bryan L. Roth and colleagues in 2003.
See also Cyclized phenethylamine Serotonin 5-HT2A receptor antagonist AMDA
References
External links SpAMDA - Isomer Design


